Amphastar Pharmaceuticals — Q3 2026 Earnings Summary

Amphastar Pharmaceuticals reported net revenues of $207.6 million for the three months ended September 30, 2026, representing an 8% increase from the prior year period. The company achieved a GAAP net income of $37.8 million, or $0.87 per diluted share, while adjusted non-GAAP net income reached $49.3 million, or $1.14 per diluted share. Sales growth was primarily driven by increased volumes and pricing for BAQSIMI and Primatene MIST, alongside contributions from newly launched products such as ipratropium bromide and teriparatide. General and administrative expenses decreased significantly due to the absence of a $23.1 million litigation provision recorded in the third quarter of 2025.